News
(Moncton, NB) - August 11th, 2017 - The Assumption Life Golf Tournament raised $55,000 for the Atlantic Cancer Research Institute (ACRI). ACRI is very grateful to Assumption Life, the tournament participants, the tournament sponsors and special guest, Guy Lafleur. Thank you!
(Moncton, Canada) - March 15th, 2017 – The Atlantic Cancer Research Institute (ACRI) is pleased to announce an agreement with BioVendor – Laboratorní medicína a.s. to license its patented intellectual property for the use of the Vn96 synthetic peptide in liquid biopsy applications. The agreement gives BioVendor non-exclusive rights to use the Vn96 peptide for the isolation of extracellular vesicles for the diagnosis of diseases, such as cancer.
Extracellular vesicles (EVs), which include exosomes, are small cell-derived particles that are present within body fluids such as plasma and urine. EVs contain a sample of the DNA, RNA, protein, lipids and metabolites found within the cells from which they are derived and therefore are a valuable source of biomarkers that reflect the real-time state of both healthy and diseased cells. The Vn96 synthetic peptide, developed by ACRI and New England Peptide Inc. (Gardner, MA), is recognized as one of the leading technologies that enables EV capture from body fluids.
Liquid biopsy is a precision medicine technology that offers physicians and health professionals the ability to test a patient in real time to obtain multi-parametric biomarker information and guide therapeutic choices. The Vn96 peptide enables liquid biopsy by providing a fast and reproducible method for the isolation of EVs, and the information that they contain, which is clinically amenable and requires minimal specialized equipment.
DOWNLOAD PDF OF PRESS RELEASE
About BioVendor
BioVendor - Laboratorni medicina a.s. was established in the Czech Republic in 1992 as a distributor of clinical chemistry and life science laboratory products. The Research and Diagnostic Products division is an innovative biotechnology company focused on the development and manufacture of in vitro diagnostics and for-research-use immunoassays, recombinant proteins and antibodies. BioVendor’s R&D assays for in vitro diagnostics are aimed at rapidly growing fields of interest within the international research and diagnostic community, such as the oncology and liquid biopsy markets.
About ACRI
The Atlantic Cancer Research Institute is a private, not-for-profit research organization created in 1998 and located at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton, NB, Canada. Unique to the region and operating a modern biomedical research laboratory, this entrepreneurial team is striving to innovate by accelerating its understanding of cancer, thus paving the way to better diagnosis, more accurate patient stratification and drug discovery.
Quotes
“The license agreement is a very important piece in our strategy to bring innovative immunoassays that target miRNA as clinically valuable biomarkers.”- Viktor Růžička, M.D., CEO of BioVendor – Laboratorní medicína a.s.
“We are very pleased to conclude this licensing agreement with an innovative company like BioVendor. We are confident that our extracellular vesicle isolation technology will be able to enhance their diagnostic and liquid biopsy products.” – Dr. Rodney Ouellette, President and Scientific Director of ACRI
-30-
For additional information, please contact:
Remi Richard, Business Development Agent
Atlantic Cancer Research Institute
T 506.862.7512
E-mail:This email address is being protected from spambots. You need JavaScript enabled to view it.
www.atlanticcancer.ca
Extracellular vesicles (EVs), which include exosomes, are small cell-derived particles that are present within body fluids such as plasma and urine. EVs contain a sample of the DNA, RNA, protein, lipids and metabolites found within the cells from which they are derived and therefore are a valuable source of biomarkers that reflect the real-time state of both healthy and diseased cells. The Vn96 synthetic peptide, developed by ACRI and New England Peptide Inc. (Gardner, MA), is recognized as one of the leading technologies that enables EV capture from body fluids.
Liquid biopsy is a precision medicine technology that offers physicians and health professionals the ability to test a patient in real time to obtain multi-parametric biomarker information and guide therapeutic choices. The Vn96 peptide enables liquid biopsy by providing a fast and reproducible method for the isolation of EVs, and the information that they contain, which is clinically amenable and requires minimal specialized equipment.
DOWNLOAD PDF OF PRESS RELEASE
About BioVendor
BioVendor - Laboratorni medicina a.s. was established in the Czech Republic in 1992 as a distributor of clinical chemistry and life science laboratory products. The Research and Diagnostic Products division is an innovative biotechnology company focused on the development and manufacture of in vitro diagnostics and for-research-use immunoassays, recombinant proteins and antibodies. BioVendor’s R&D assays for in vitro diagnostics are aimed at rapidly growing fields of interest within the international research and diagnostic community, such as the oncology and liquid biopsy markets.
About ACRI
The Atlantic Cancer Research Institute is a private, not-for-profit research organization created in 1998 and located at the Dr. Georges-L.-Dumont University Hospital Centre in Moncton, NB, Canada. Unique to the region and operating a modern biomedical research laboratory, this entrepreneurial team is striving to innovate by accelerating its understanding of cancer, thus paving the way to better diagnosis, more accurate patient stratification and drug discovery.
Quotes
“The license agreement is a very important piece in our strategy to bring innovative immunoassays that target miRNA as clinically valuable biomarkers.”- Viktor Růžička, M.D., CEO of BioVendor – Laboratorní medicína a.s.
“We are very pleased to conclude this licensing agreement with an innovative company like BioVendor. We are confident that our extracellular vesicle isolation technology will be able to enhance their diagnostic and liquid biopsy products.” – Dr. Rodney Ouellette, President and Scientific Director of ACRI
-30-
For additional information, please contact:
Remi Richard, Business Development Agent
Atlantic Cancer Research Institute
T 506.862.7512
E-mail:
www.atlanticcancer.ca
(Moncton, NB) – February 4th, 2017 – World Cancer Day, which takes place every year on February 4th, is an initiative under which the entire world can unite together in the fight against the global cancer epidemic. With research facilities located in Moncton, New Brunswick, the Atlantic Cancer Research Institute (ACRI) is an integral part of efforts of the world-wide scientific community to progress the battle against cancer.
“Breakthroughs in our knowledge of cancer biology are the key that allows innovation to reach the cancer patient.” says Dr. Rodney Ouellette, President and Scientific Director at ACRI. “This new knowledge allows for the development of improved tests for early detection and diagnosis on the one hand, while leading to improved tailoring of new treatments to the individual. We can now say that we are routinely analyzing individual cancer genomes and with our liquid biopsy technologies we are moving towards the real-time personalization of patient care.”
September 14, 2016 Moncton – NB – (Atlantic Canada Opportunities Agency – ACOA)
Testing patients for cancer and other diseases will become more efficient and less painful as a result of an investment of up to $3 million from the Government of Canada.
(Moncton, NB) – August 16, 2016 - The Atlantic Cancer Research Institute (ACRI) is pleased to welcome Dr. Sylvain Mailhot as an Associate Researcher.
‘Personalize My Treatment’ (PMT) Initiative aims to:
• Make Canada’s rich scientific resources accessible to the research community
• Create a comprehensive cancer database of tissue samples, genomic data and clinical
data from the cancer patient population
• Match patients to available clinical trials based on the profile of their cancer
Moncton, New Brunswick - April 18, 2016 - At an announcement made earlier today at the Dr. Georges-L.-Dumont University Hospital Centre, Merck, known as MSD outside the United States and Canada, confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative. In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute $1 million each to help bring innovative precision medicine to Canadians living with cancer.
• Make Canada’s rich scientific resources accessible to the research community
• Create a comprehensive cancer database of tissue samples, genomic data and clinical
data from the cancer patient population
• Match patients to available clinical trials based on the profile of their cancer
Moncton, New Brunswick - April 18, 2016 - At an announcement made earlier today at the Dr. Georges-L.-Dumont University Hospital Centre, Merck, known as MSD outside the United States and Canada, confirmed its commitment to research and innovation in oncology by contributing a total of $2 million to the Exactis Innovation ‘Personalize My Treatment’ (PMT) initiative. In addition, the Cancer Research Society (CRS) and the New Brunswick Health Research Foundation (NBHRF) will also contribute $1 million each to help bring innovative precision medicine to Canadians living with cancer.
(Moncton, N.B.) – March 30, 2016 - The Atlantic Cancer Research Institute (ACRI) today announced the successful completion of a $10 million fundraising campaign, the largest in the Institute’s celebrated 15 year history.
“Over its first fifteen years the Atlantic Cancer Research Institute has had some significant accomplishments and now with the successful completion of this $10 million fundraising campaign the Institute is looking toward an even brighter future,” according to ACRI President Dr. Rodney Ouellette.
“Over its first fifteen years the Atlantic Cancer Research Institute has had some significant accomplishments and now with the successful completion of this $10 million fundraising campaign the Institute is looking toward an even brighter future,” according to ACRI President Dr. Rodney Ouellette.
(Moncton, N.B.) – March 21, 2016 -- The Atlantic Cancer Research Institute (ACRI) will present improvements on its patented peptide-based extracellular vesicle isolation technology today at the Circulating Biomarkers World Congress (CBWC) in Boston. These enhancements to this first-in-class liquid biopsy-enabling technology will open up opportunities for better disease management as it applies to early detection, diagnosis and monitoring of treatment response. This technology yields cancer biomarkers using a minimally-invasive approach that complements and may eventually eliminate the need for invasive tissue biopsies as a means to identify and monitor disease in real time.
